De Novo Sequencing And Comparative Genomic Study For Janibacter Clinical Isolate

In our study, we isolated a rare bacterial –Janibacter, during the process of clinical microbiology diagnosis. We amplified 16 s rDNA the isolate and sequenced, sequence alignment, determined the isolate belong to Janibacter genus.And we named Janibacter YFY001 strains in this study. Meanwhile, we verified that the bacterial susceptibility testing, found YFY001 was resistant to rifampicin, ceftazidime and clindamycin. Since then, we extracted the entire genome of YFY001, then combined with a second-generation and third-generation genome sequencing technology, access to the whole genome YFY001 strains. Finally, we found YFY001 strain genome size 3.40 Mbp, GC% to 71.46%. We used comparative genomics research methods, to compare YFY001 strains with two strains of environmental strains have been reported: HTCC2469 and holey. Eventually we found 911 core proteins; while 1039 proteins specifically present in YFY001 strain. With this paper, the method of whole-genome sequencing of clinical isolates of high GC content Janibacter YFY001, a combination of the second and third generation sequencing technology, eventually won the whole genome sequence YFY001 strains. In whole-genome YFY001 strains, we found a protein associated with pathogenicity two-component regulatory system, secretion system. Compared with the environment found in the genome of strain-specific protein YFY001 strains present in its pathogenicity may also have a certain relationship. In this study, combined with genome sequencing technology, the rare strain of clinical isolates of whole genome sequencing of these bacteria to clarify the causative agent for the treatment of patients infected with timely provide the necessary basis.